Industry Pharmaceuticals Website sigmaco.com.au Revenue 3 billion AUD Net income 53.5 million AUD | Area served Worldwide Headquarters Croydon, United Kingdom Number of employees 850 | |
Type Public company (ASX:SIP) Key people Brian Jamieson (Chairman)
Mark Hooper (CEO & managing director) Products Prescription, Over-the-counter and Generic Pharmaceutical Products Stock price SIP (ASX) A$ 1.25 +0.02 (+1.63%)21 Mar, 4:10 PM GMT+11 - Disclaimer Founded 1912, Melbourne, Australia Subsidiaries Amcal, Herron Pharmaceuticals, QDL Ltd. Profiles | ||
Bharat shah managing director sigma pharmaceuticals at the sigma conference 2015
Sigma Pharmaceuticals Limited is a full line wholesale and distribution business to pharmacy. It is also the owner of Australia's best known pharmacy retail brands: Amcal Max, DDS, Amcal and Guardian. Guardian should not to be confused with the East Asian pharmacy Guardian.
Contents
- Bharat shah managing director sigma pharmaceuticals at the sigma conference 2015
- Sigma pharmaceuticals turns a corner
- 2010 restructure
- Financial performance
- Mergers acquisitions
- 2010 trading halt
- References
Sigma pharmaceuticals turns a corner
2010 restructure
Sigma restructured in 2010, disposing of its generic drug manufacturing business.
Financial performance
The company's sales revenue grew 1.1 percent to $3 billion in 2013-14, while net profit climbed 187 percent to $53.5 million.
Mergers & acquisitions
In March 2014, Sigma acquired Central Healthcare Services, in a deal worth $24.5 million. In September 2014, the company bought the Queensland-based Discount Drug Store (DDS) banner for $26.7 million. The DDS acquisition was set to add 120 pharmacies under that brand to the Sigma network.
2010 trading halt
In 2010, Sigma shares were placed in a trading halt on the Australian Stock Exchange – initially due to a profit warning. Since then, allegations of accounting irregularities and preferential deals negotiated with certain pharmacy chains (at the expense of smaller independent chemists) that left Sigma losing money at the expense of their own Amcal and Guardian Pharmacies banners and forsaking cashflow emerged. The trading halt was lifted later that year. The events resulted in the initiation of a shareholder class action before the Federal Court of Australia.